Folic Acid 59-30-3 99
Folic acid Basic information
Description
Product Name: Folic acid
Synonyms: EZNA KIT FUNGAL DNA MINI;KIT BLOOD DNA EZNA 5 TESTS;PTEROYL-L-GLUTAMIC ACID;PTEROYLMONOGLUTAMIC ACID;PTEROYLGLUTAMIC ACID;PTEROYGLUTAMIC ACID;PTEGLU;PGA
CAS: 59-30-3
MF: C19H19N7O6
MW: 441.4
EINECS: 200-419-0
Product Categories: Inhibitors;Nutritional Supplements;Food and Feed Additive;Biochemistry;Vitamin Ingredients;food or feed additives;Vitamins;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;FOLICET;vitamin;raw material;Intermediates & Fine Chemicals;Pharmaceuticals;standardized herbal extract;59-30-3
Mol File: 59-30-3.mol
Folic acid Chemical Properties
Melting point 250 °C
alpha 20 º (c=1, 0.1N NaOH)
Boiling point 552.35°C (rough estimate)
density 1.4704 (rough estimate)
refractive index 1.6800 (estimate)
storage temp. 2-8°C
solubility boiling water: soluble1%
form Crystalline Powder
pka pKa 2.5 (Uncertain)
color Yellow to orange
Odor Odorless
PH Range 4
Water Solubility 1.6 mg/L (25 ºC)
Merck 14,4221
BRN 100781
BCS Class 3
Stability: Stable. Incompatible with heavy metal ions, strong oxidizing agents, strong reducing agents. Solutions may be light and heat sensitive.
InChIKey OVBPIULPVIDEAO-LBPRGKRZSA-N
LogP -0.990 (est)
CAS DataBase Reference 59-30-3(CAS DataBase Reference)
NIST Chemistry Reference Folic acid(59-30-3)
EPA Substance Registry System L-Glutamic acid, N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]- (59-30-3)
Safety Information
Risk Statements 33-62-68
Safety Statements 24/25
WGK Germany 1
RTECS LP5425000
F 8
TSCA Yes
HS Code 29362900
Hazardous Substances Data 59-30-3(Hazardous Substances Data)
Toxicity A water soluble vitamin required in the diet of mammals. Sulfonamide drugs are selectively toxic to bacteria because they inhibit the incorporation of p-aminobenzoic acid into folic acid, a biosynthetic process in bacteria. Folic acid deficiency adversely affects prenatal development in humans. Dietary supplementation with folic acid dramatically reduces the incidence of neural tube defects in humans. Folic acid deficiency may also contribute to the causes of megaloblastic macrocytic anemia and a consequence of this is that this disease can be induced, as a side effect, when methotrexate, a folic acid antagonist, is used in cancer chemotherapy
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View